Guggenheim Names Top Biotechnology Stock Pick

Guggenheim analyst Yatin Suneja has spotlighted a standout opportunity in the biotechnology sector, drawing attention to a company making headway in therapies for eye disorders.

The top pick comes as the industry intensifies its focus on novel treatments for substantial unmet needs in ophthalmology. Suneja's selection is grounded in recent regulatory milestones and imminent clinical catalysts that could steer the company's future.

1. Surrozen Inc (NASDAQ:SRZN) — Top Pick

Surrozen has submitted an Investigational New Drug application for SZN-8141, a bispecific therapy that pairs Wnt agonism with an anti-VEGF component for diabetic macular edema. If the IND clears, the company will receive the second tranche of $98.4 million from its 2025 financing round, which totals $175 million. Those funds are anticipated to underwrite operations through the Phase Ib/IIa DUET study and a Phase I safety, tolerability, and efficacy trial for SZN-8143, a candidate combining FZD4 and LRP5/6 with anti-VEGF and anti-IL-6 mechanisms. Guggenheim projects a smooth IND clearance in the next 30 days. Surrozen is also on schedule to start the Phase Ib/IIa DUET study in patients with diabetic macular edema by end-2026, followed by early Phase Ib single ascending dose data and a possible interim analysis in Phase IIa. The analyst further points to Merck's BRUNELLO study, due for presentation on October 10, 2026, at the American Academy of Ophthalmology meeting. That study involved 984 patients, with topline results expected before the conference. Guggenheim argues that a positive outcome—whether statistically significant or showing numerical trends in best corrected visual acuity or central subfield thickness—could carry substantial weight for the sector, given that no mechanism has yet demonstrated non-inferiority against anti-VEGFs in pivotal trials for diabetic macular edema or wet age-related macular degeneration.

This article was generated with the help of AI and reviewed by an editor. For more information, see our Terms and Conditions.